

# Guy Berchem MD., PhD



Guy Berchem MD., PhD

PROFESSOR

Lung Cancer, Gastrointestinal and Neuro-Oncology Specialist

Founder and head of Experimental Cancer Research Laboratory at Health Institute of Luxembourg (LIH). He is president of the Luxemburg Society of Medical Oncology (SLO) and holds a clinical position leading the oncology platform at Hospital Medical Center of Oncology in Luxembourg. He has more than 70 international scientific publications as author and co-author.

**Full name:** Guy Berchem

**Country:** Luxembourg

**Current Position:**

|              |   |
|--------------|---|
| 2016-present | President. National Cancer Institute (INC). Luxembourg.   |
| 2004-present | Head of Laboratory of Experimental Hemato-Oncology Laboratory (LHCE) at the Public Health Research Center (CRP-Santé), biology and cell death research, immunotherapy and biomarkers. Luxembourg. |
| 2001-present | President of SLO.   |
| 1999-present | Medical oncologist. Hospital Center of Luxembourg (CHL).  |

**Education:**

|      |   |
|------|---|
| 2014 | PhD Thesis. Role of hypoxic stress in the regulation of the antitumor immune response mediated by natural killer. University South Paris. France. |
| 1996 | Specialist in medical oncology and internal medicine. ULB. Belgium.   |
| 1995 | Postdoctoral scholarship. Cancer Center Lombardi. Georgetown University. USA.   |
| 1990 | Doctor of medicine, surgery, and births. Free University of Brucellas (ULB). Belgium.   |

**Experience:**

|              |  |
|--------------|--|
| 2016-present | President. INC. Luxembourg.  |
| 2004-present | Head of LHCE, CRP-Sante, biology and cell death research, immunotherapy and biomarkers. Luxembourg.          |
| 2001-present | President of SLO.  |
| 1999-present | Medical oncologist. CHL. Luxembourg.   |
| 1996-1998    | Medical oncologist. Cancer Center of the Bordet Institute in Brussels. Belgium.                              |
| 1996-1998    | Research fellow (National Research Fund of Belgium). Cancer Center of Bordet Institute in Brussels. Belgium. |

**Scientific publications:**

Number of publications as author or co-author: 78

Books: 1

Book chapters: 5

Recent scientific publications:

Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5- dependent manner. Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, Van Moer K, Kreis S, Guerin C, Buart S, Robert C, Borg C, Vielh P, Chouaib S, Berchem G, Janji B. Proc Natl Acad Sci U S A. 2017 Oct 31;114(44).

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Giuliani M, Janji B, Berchem G. Oncotarget. 2017 Feb 9.